Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLBENEMID vs COLYTE-FLAVORED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammation. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion.
Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery,Bowel preparation for barium enema
Adults: 1 tablet (probenecid 500 mg / colchicine 0.5 mg) orally once daily for first week, then twice daily thereafter. May increase to 3-4 tablets daily in divided doses if needed.
4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.
Probenecid: 6-12 hours (dose-dependent); colchicine: 20-30 hours (terminal) in renal impairment may prolong.
Not applicable; the drug acts locally in the gastrointestinal tract without significant systemic absorption. For the small fraction absorbed, a terminal elimination half-life of approximately 0.5-1 hour is estimated, but clinical relevance is negligible.
Colchicine: primarily hepatic via CYP3A4; Probenecid: hepatic metabolism via glucuronidation and oxidation.
Polyethylene glycol (PEG) is not significantly metabolized; it is excreted unchanged in feces.
Renal: ~76% as unchanged probenecid and metabolites; biliary/fecal: minor (<5%). Colchicine: ~20% renal, ~80% fecal primarily via biliary excretion.
Primarily eliminated in feces (≥95%) as intact drug via the gastrointestinal tract. Minimal systemic absorption; renal excretion accounts for <1% of the administered dose.
Probenecid: ~85-95% primarily to albumin; colchicine: ~30-50% to albumin and other proteins.
Negligible (<5%) due to minimal systemic absorption; no specific binding proteins identified.
Probenecid: 0.15-0.2 L/kg (confined to plasma and extracellular fluid); colchicine: 2-8 L/kg (wide tissue distribution, high in leukocytes).
Not meaningful due to negligible systemic absorption. The small fraction absorbed distributes primarily in extracellular fluid; a theoretical Vd would be low (<0.2 L/kg), but not clinically relevant.
Probenecid: ~100% oral; colchicine: ~45% oral (range 25-50%) with significant first-pass metabolism.
Oral bioavailability is <1% due to minimal gastrointestinal absorption; the drug acts locally within the intestinal lumen.
Cr Cl <50 m L/min: contraindicated. Cr Cl 50-80 m L/min: reduce dose by 50% or extend interval. Cr Cl >80 m L/min: no adjustment.
Use with caution in patients with GFR <30 m L/min/1.73 m2; consider alternative bowel preparation. No specific dose adjustment defined.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or use with caution. Child-Pugh C: contraindicated (risk of colchicine accumulation).
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to risk of fluid and electrolyte disturbances.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for use in children; safety and efficacy not established.
Start at lowest dose (e.g., 1 tablet daily) and titrate slowly; monitor renal function and avoid in Cr Cl <50 m L/min. Consider reduced doses due to increased risk of toxicity.
Use with caution; monitor for fluid and electrolyte imbalances, renal function, and volume status. Consider lower dose or split-dose regimen.
No FDA boxed warning.
There is no FDA black box warning for Colyte.
Severe toxicity with colchicine in renal/hepatic impairment; blood dyscrasias (probenecid); increased risk of colchicine toxicity with CYP3A4 inhibitors; avoid use with NSAIDs due to increased GI toxicity.
Risk of aspiration and esophageal perforation in patients with impaired gag reflex or altered consciousness,Electrolyte disturbances (e.g., hypernatremia, hypokalemia) in patients with renal impairment or dehydration,Cardiac arrhythmias in patients with electrolyte imbalances or QT prolongation,Colonic mucosal erosions or ulcerations with repeated use,Not for use in patients with gastrointestinal obstruction, perforation, or ileus
Hypersensitivity to colchicine or probenecid; severe renal impairment (Cr Cl < 30 m L/min); concurrent use of P-glycoprotein or strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) with colchicine; blood dyscrasias; peptic ulcer disease; acute gout flare treatment with history of uric acid renal calculi.
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,History of severe electrolyte abnormalities,Known hypersensitivity to any component
Alcohol reduces efficacy and increases hyperuricemia; avoid completely. High-purine foods (e.g., red meat, organ meats, sardines, mussels) may exacerbate gout. Grapefruit juice may increase colchicine toxicity via CYP3A4 inhibition. Acidic foods (e.g., cranberries, prunes) can decrease urine p H and increase uric acid crystallization risk. Maintain adequate hydration with water.
Only clear liquids are allowed during bowel preparation. Avoid milk, cream, soups with solid ingredients, red or purple liquids, and alcohol. Solid food should be avoided at least 2 hours before starting the solution. No food interactions with the drug itself; dietary restrictions are for the procedure.
Colbenemid is a combination of colchicine and probenecid. Colchicine is associated with increased risk of fetal harm when administered during pregnancy, including chromosomal abnormalities and fetal death, particularly in the first trimester. Probenecid should be avoided in pregnancy due to potential teratogenic effects and neonatal toxicity. Overall, use is contraindicated in pregnant women.
Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.
Colchicine is excreted into human milk with a milk-to-plasma ratio (M/P ratio) of approximately 0.9. Probenecid passes into breast milk in small amounts. Due to potential serious adverse effects in nursing infants, including gastrointestinal toxicity and bone marrow suppression, breastfeeding is not recommended during therapy.
Excretion unknown; likely minimal systemic absorption. No M/P ratio available. Use with caution.
No specific dose adjustment guidelines exist due to contraindication during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) may reduce efficacy, but use is not recommended.
No dosage adjustment required; monitor for hypovolemia due to increased plasma volume.
Colbenemid is a fixed-dose combination of colchicine (0.5 mg) and probenecid (500 mg). Probenecid increases uric acid excretion by inhibiting renal tubular reabsorption; colchicine reduces gout flare inflammation. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) or peptic ulcer disease. Probenecid can increase serum levels of penicillins, cephalosporins, and NSAIDs. Colchicine toxicity risk increases with concurrent P-glycoprotein or CYP3A4 inhibitors (e.g., clarithromycin, cyclosporine). Monitor for myopathy and neuropathy. May cause a false-positive urinary glucose test.
Colyte-Flavored (PEG-3350 and electrolytes) is a colonic lavage solution used for bowel preparation prior to colonoscopy. Ensure adequate hydration: patients must consume all 4 liters (or split-dose regimen). Concurrent use of other laxatives or enemas is generally not needed. In patients with impaired gag reflex, renal insufficiency, or electrolyte abnormalities, use with caution. Monitor for bloating, nausea, and aspiration risk. Avoid use in GI obstruction, toxic colitis, or megacolon.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2-3 liters of fluid daily to prevent kidney stones.,Avoid alcohol and high-purine foods (organ meats, shellfish) during therapy.,Report signs of toxicity: muscle weakness, numbness, tingling, severe diarrhea, or vomiting.,Do not take with macrolide antibiotics or antifungal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
Do not add any other ingredients to the solution.,Chill the solution before drinking to improve palatability.,Drink the entire volume over the prescribed period; do not eat solid foods until after the procedure.,Expect frequent, watery bowel movements; stay near a toilet.,Take other medications at least 1 hour before starting the solution, except as directed by your doctor.,Stop drinking the solution 2-3 hours before the procedure.,If severe bloating, abdominal pain, or vomiting occurs, pause and resume later.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLBENEMID vs COLYTE-FLAVORED, answered by our medical review team.
COLBENEMID is a Antigout Agent Combination that works by Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammation. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion.. COLYTE-FLAVORED is a Osmotic Laxative that works by Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLBENEMID and COLYTE-FLAVORED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLBENEMID is: Adults: 1 tablet (probenecid 500 mg / colchicine 0.5 mg) orally once daily for first week, then twice daily thereafter. May increase to 3-4 tablets daily in divided doses if needed.. The standard adult dose of COLYTE-FLAVORED is: 4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLBENEMID and COLYTE-FLAVORED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLBENEMID is classified as Category C. Colbenemid is a combination of colchicine and probenecid. Colchicine is associated with increased risk of fetal harm when administered during pregnancy, including chromosomal abnor. COLYTE-FLAVORED is classified as Category C. Category C: Not associated with major malformations; limited data in pregnancy. No known teratogenicity; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.